Get started
MAYNE PHARMA GROUP LIMITEDMAYNE PHARMA GROUP LIMITEDMAYNE PHARMA GROUP LIMITED

MAYNE PHARMA GROUP LIMITED

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

MYX chart


Full chart

MYX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪385.92 M‬ AUD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.14 AUD
Net income (FY)
‪−174.23 M‬ AUD
Revenue (FY)
‪388.40 M‬ AUD
Shares float
‪61.79 M‬
Beta (1Y)
2.40

Employees


Employees (FY)
450
Change (1Y)
0
Revenue / Employee (1Y)
‪863.11 K‬ AUD
Net income / Employee (1Y)
‪−374.71 K‬ AUD

About MAYNE PHARMA GROUP LIMITED


Sector
Health Technology
CEO
Shawn Patrick O'Brien
Headquarters
Salisbury
Website
maynepharma.com
Founded
2005
ISIN
AU000000MYX0
FIGI
BBG000BLN6N6
Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. It operates through the following segments: Generic Products, Specialty Products, Metrics Contract Services, and Mayne Pharma International. The Generic Products segment is involved in the manufacture and distribution of generic and branded pharmaceutical products. The Metrics Contract Services segment provides contract pharmaceutical services. The Specialty Products segment includes the distribution of branded pharmaceutical products. The Mayne Pharma International segment manufactures and sells branded and generic pharmaceutical products and provides contract manufacturing services to third party customers within Australia. The company was founded in 1845 and is headquartered in Salisbury, Australia.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

MYX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of MYX is 4.75 AUD — it has decreased by −2.06% in the past 24 hours. Watch MAYNE PHARMA GROUP LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange MAYNE PHARMA GROUP LIMITED stocks are traded under the ticker MYX.
MYX stock has fallen by −2.06% compared to the previous week, the month change is a 2.37% rise, over the last year MAYNE PHARMA GROUP LIMITED has showed a −23.76% decrease.
We've gathered analysts' opinions on MAYNE PHARMA GROUP LIMITED future price: according to them, MYX price has a max estimate of 6.25 AUD and a min estimate of 5.95 AUD. Watch MYX chart and read a more detailed MAYNE PHARMA GROUP LIMITED stock forecast: see what analysts think of MAYNE PHARMA GROUP LIMITED and suggest that you do with its stocks.
MYX reached its all-time high on Aug 15, 2016 with the price of 42.20 AUD, and its all-time low was 2.68 AUD and was reached on Feb 8, 2023. View more price dynamics on MYX chart.
See other stocks reaching their highest and lowest prices.
MYX stock is 4.30% volatile and has beta coefficient of 2.40. Track MAYNE PHARMA GROUP LIMITED stock price on the chart and check out the list of the most volatile stocks — is MAYNE PHARMA GROUP LIMITED there?
Today MAYNE PHARMA GROUP LIMITED has the market capitalization of ‪385.92 M‬, it has increased by 0.20% over the last week.
Yes, you can track MAYNE PHARMA GROUP LIMITED financials in yearly and quarterly reports right on TradingView.
MAYNE PHARMA GROUP LIMITED is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
MYX earnings for the last half-year are 0.00 AUD per share, whereas the estimation was −0.22 AUD, resulting in a 100.45% surprise. The estimated earnings for the next half-year are −0.13 AUD per share. See more details about MAYNE PHARMA GROUP LIMITED earnings.
MAYNE PHARMA GROUP LIMITED revenue for the last half-year amounts to ‪200.45 M‬ AUD, despite the estimated figure of ‪202.00 M‬ AUD. In the next half-year revenue is expected to reach ‪198.50 M‬ AUD.
MYX net income for the last half-year is ‪−103.68 M‬ AUD, while the previous report showed ‪−70.55 M‬ AUD of net income which accounts for −46.96% change. Track more MAYNE PHARMA GROUP LIMITED financial stats to get the full picture.
As of Dec 22, 2024, the company has 450.00 employees. See our rating of the largest employees — is MAYNE PHARMA GROUP LIMITED on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MAYNE PHARMA GROUP LIMITED EBITDA is ‪−9.38 M‬ AUD, and current EBITDA margin is −2.41%. See more stats in MAYNE PHARMA GROUP LIMITED financial statements.
Like other stocks, MYX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MAYNE PHARMA GROUP LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MAYNE PHARMA GROUP LIMITED technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MAYNE PHARMA GROUP LIMITED stock shows the sell signal. See more of MAYNE PHARMA GROUP LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.